新型雄激素受体拮抗剂治疗去势抵抗性前列腺癌的研究进展

摘要

Prostate cancer is one of the common malignant tumors in male reproductive system.It is currently accepted that the progression of prostate cancer is related to androgen receptor ( AR) and AR reaction pathway.The clinical treat-ment becomes more complicated when it progresses to castration-resistant prostate cancer ( CRPC) .The clinical trial have shown that three novel AR antagonists, including Enzalutamide, ARN-509and ONC1-13B, are effective and have minor adverse reactions.Therefore, application of AR antagonists in the treatment of CRPC is becoming increasingly important.%前列腺癌的进展与雄激素受体（ androgen receptor，AR）以及AR反应通路相关，进展期前列腺癌患者需接受雄激素阻断治疗，而去势抵抗性前列腺癌（ castration－resistant prostate cancer，CRPC）的临床治疗更加复杂。 Enz-alutamide，ARN－509，ONC1－13B三种新型AR拮抗剂是用于AR的靶向药物，临床研究正在进行中。 AR拮抗剂效果明显且副作用小，因此应用这一类药物治疗CRPC的方法便日益凸显其重要性。